Leggett Thomas 4

What Happened Thomas Leggett, Chief Financial Officer of Stoke Therapeutics (STOK), disposed of a total of 4,578 shares via open-market sales on March 17–18, 2026, generating aggregate proceeds of approximately $147,145. Individual reported lots: 1,274 shares @ $32.74 ($41,710); 922 shares @ $33.38 ($30,772); 2,173 shares @ $31.28 ($67,980); 172 shares @ $31.79 ($5,468); and 37 shares @ $32.85 ($1,215). These transactions are coded as sales (S) and were reported on a Form 4 filed March 19, 2026.

Key Details

• Transaction dates: March 17–18, 2026; Form 4 filed March 19, 2026 (within normal reporting window).
• Total shares sold: 4,578; approximate total proceeds: $147,145.
• Reported prices: weighted averages; reported per‑lot amounts noted above. Footnotes indicate per‑share price ranges across multiple executions:
  • F2: $31.995–$32.99
  • F3: $33.00–$33.855
  • F4: $30.59–$31.58
  • F5: $31.60–$32.46
• Footnote F1: sales were issuer‑mandated to satisfy tax‑withholding liabilities in connection with the vesting/settlement of restricted stock units (a “sell‑to‑cover”).
• Shares owned after the transactions: not specified in the supplied filing details.

Context These were sell transactions to cover tax withholding on RSU vesting (routine "sell‑to‑cover"), not an open‑market discretionary purchase or sale intended to signal a change in conviction. The weighted‑average prices reflect multiple executions across the stated ranges; the reporting person offered to provide detailed per‑trade price breakdowns on request. For retail investors, purchases generally carry more direct informational weight than mandated sell‑to‑cover transactions.